Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 in HABP and VABP Caused by CRABC
NCT07326540Phase 3Recruiting
- Sponsor
- BioVersys AG
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BV100 in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by BioVersys AG. Started Mar 2026; status: recruiting.
02
Drugs
BV100
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07326540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326540.